Skip to main content

Pharma News

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • Lupin Receives approval from USFDA for Dolutegravir, Emtricitabine and Tenofovir Alafenamide Tablets

    Lupin Limited announced that it has received tentative approval from the United States Food and Drug Administration (FDA) under the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) for its New Drug Application for Dolutegravir, Emtricitabine and Tenofovir Alafenamide (DETAF) Tablets. This product would be manufactured at Lupin’s Nagpur facility in India.

    DETAF would be a welcome new addition in the management of HIV infections and will be available for supplies to low- & middle-income countries.

  • Pfizer accepts it engineered new Covid mutation

    Pfizer said that it has conducted research where the original SARS-CoV-2 virus has been used to express the spike protein from new variants of concern. This work is undertaken once a new variant of concern has been identified by public health authorities.

  • Alchem launches Ceftazidime - Avibactam injection against MDR infections in India

    Alkem has announced the launch of its novel anti-infective Ceftazidime-Avibactam injection, under the brand name, Zidavi in India. It is known to be effective against multi-drug resistance, MDR infections.

    In India, with the rise in carbapenem-resistant Gram-negative organisms, there is a need for treatments more effective than the existing antibiotics. Zidavi is a 3rd generation antibiotic.

  • Possible underlying cause of dementia detected

    A new Cedars-Sinai study suggests that some patients diagnosed with behavioral-variant frontotemporal dementia (bvFTD)—an incurable condition that robs patients of the ability to control their behavior and cope with daily living—may instead have a cerebrospinal fluid leak, which is often treatable.

    Researchers say these findings, published in the peer-reviewed journal Alzheimer’s & Dementia: Translational Research and Clinical Interventions, may point the way to a cure.

  • Mimicking an Enigmatic Property of Circadian Rhythms through an Artificial Chemical Clock

    An innovative temperature-compensation mechanism for oscillating chemical reactions based on temperature-responsive gels has been recently reported by researchers at Tokyo Tech. Their experimental findings, alongside a detailed mathematical analysis, hint at the possibility that circadian rhythms found in nature may all rely on a similar mechanism, allowing their period to remain independent of temperature.

  • WHO and Gilead Sciences extends research on treatment for visceral leishmaniasis

    The World Health Organization (WHO) and Gilead Sciences have signed a new agreement for the donation of 304,700 vials of AmBisome (liposomal amphotericin B for injection), for the treatment of visceral leishmaniasis in countries most impacted by the disease, extending their previous agreement to 2025.

  • Glenmark launches AKYNZEO I.V. in India

    Glenmark Pharmaceuticals Ltd, an innovation-driven, global pharmaceutical company, is the first to launch in India a unique I.V. injection formulation, AKYNZEO® I.V., for the prevention of chemotherapy-induced nausea and vomiting (CINV), under an exclusive licensing agreement with Helsinn, a Swiss biopharma group company.

  • Granules Pharma receives ANDA Approval for Amphetamine Mixed Salts ER Capsules

    Granules India Limited announced that the US Food & Drug Administration (US FDA) has approved the Abbreviated New Drug Application (ANDA) filed by Granules Pharmaceuticals, Inc (GPI)., a wholly-owned foreign subsidiary of the company, for Amphetamine Mixed Salts, 5mg, 10mg, 15mg, 20mg, 25mg, and 30mg Extended-Release (ER) capsules. It is bioequivalent to the reference listed drug product (RLD), Adderall XR® Extended-Release capsules of Takeda Pharmaceuticals USA Inc.

  • Hypertension drug could be repurposed to delay ageing : study finds

    Researchers have found that the drug rilmenidine can extend lifespan and slow ageing.

    Published in Aging Cell, the findings show that animals treated with rilmenidine, currently used to treat hypertension, at young and older ages increases lifespan and improves health markers, mimicking the effects of caloric restriction.

  • Targeted test for antibiotic resistance in clinical Enterobacter species

    Bacteria of the genus Enterobacter are among the most dangerous bacteria associated with hospital infections worldwide. Some of their representatives are highly resistant to commonly used antibiotics, so that the reserve antibiotic colistin is increasingly used as a last resort therapy option. To avoid unnecessary reliance on colistin and risk increasing resistance, bacteria are tested for sensitivity or resistance to colistin before recommending treatment. However, commonly used tests for Enterobacter are not reliable.

Subscribe to Pharma News